{"transactions":[{"id":1029424,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":2,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":74740,"kind":"organization","name":"Cormorant Private Healthcare Fund II, LP","position":4,"cik":"0001747677","reported_name":"Cormorant Private Healthcare Fund II, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":5,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":74741,"kind":"organization","name":"Cormorant Private Healthcare Fund IV LP","position":6,"cik":"0001871297","reported_name":"Cormorant Private Healthcare Fund IV LP","relationship":{"other":true,"other_text":"Former 10% Owner"}}],"security":"Class A Ordinary Shares","published_at":"2025-10-01T21:22:38.000Z","date":"2025-09-30","kind":"sale","planned":false,"acquired":false,"shares":5827,"price":6.96,"value":40555.92,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents the weighted average sale price of Class A Ordinary Shares (\"Shares\") sold in a series of open market transactions on the transaction date at prices ranging from $6.94 to $6.99 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares sold at each price. All of these Shares were sold by the Account."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund II, LP (\"Fund II\"), Cormorant Private Healthcare Fund III, LP (\"Fund III\"), Cormorant Private Healthcare Fund IV, LP (\"Fund IV\") and a managed account (the \"Account\" and together with the Master Fund, Fund II, Fund III and Fund IV, the \"Funds\")). Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP II, LLC (\"GP II\"), Cormorant Private Healthcare GP III, LLC (\"GP III\") and Cormorant Private Healthcare GP IV, LLC (\"GP IV\") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"Represents (i) 638,740 Shares beneficially owned by the Master Fund, (ii) 424,466 Shares beneficially owned by Fund II, (iii) 577,783 Shares beneficially owned by Fund III, and (iv) 353,184 Shares beneficially owned by Fund IV."}],"balance_after":1994173,"source":{"system":"sec-edgar","filing":"0000929638-25-003712","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963825003712/form4.xml","form_type":"4"}},{"id":1029423,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":2,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":74740,"kind":"organization","name":"Cormorant Private Healthcare Fund II, LP","position":4,"cik":"0001747677","reported_name":"Cormorant Private Healthcare Fund II, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":5,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":74741,"kind":"organization","name":"Cormorant Private Healthcare Fund IV LP","position":6,"cik":"0001871297","reported_name":"Cormorant Private Healthcare Fund IV LP","relationship":{"other":true,"other_text":"Former 10% Owner"}}],"security":"Class A Ordinary Shares","published_at":"2025-10-01T21:22:38.000Z","date":"2025-09-29","kind":"sale","planned":false,"acquired":false,"shares":2800000,"price":6.61,"value":18508000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents the weighted average sale price of Class A Ordinary Shares (\"Shares\") sold in a series of open market transactions on the transaction date at prices ranging from $6.20 to $7.04 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares sold at each price. All of these Shares were sold by the Master Fund, Fund II, Fund III, Fund IV, and the Account."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund II, LP (\"Fund II\"), Cormorant Private Healthcare Fund III, LP (\"Fund III\"), Cormorant Private Healthcare Fund IV, LP (\"Fund IV\") and a managed account (the \"Account\" and together with the Master Fund, Fund II, Fund III and Fund IV, the \"Funds\")). Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP II, LLC (\"GP II\"), Cormorant Private Healthcare GP III, LLC (\"GP III\") and Cormorant Private Healthcare GP IV, LLC (\"GP IV\") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Represents (i) 638,740 Shares beneficially owned by the Master Fund, (ii) 424,466 Shares beneficially owned by Fund II, (iii) 577,783 Shares beneficially owned by Fund III, (iv) 353,184 Shares beneficially owned by Fund IV, and (v) 5,827 shares beneficially owned by the Account."}],"balance_after":2000000,"source":{"system":"sec-edgar","filing":"0000929638-25-003712","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963825003712/form4.xml","form_type":"4"}},{"id":1029422,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":2,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":74740,"kind":"organization","name":"Cormorant Private Healthcare Fund II, LP","position":4,"cik":"0001747677","reported_name":"Cormorant Private Healthcare Fund II, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":5,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":74741,"kind":"organization","name":"Cormorant Private Healthcare Fund IV LP","position":6,"cik":"0001871297","reported_name":"Cormorant Private Healthcare Fund IV LP","relationship":{"other":true,"other_text":"Former 10% Owner"}}],"security":"Class A Ordinary Shares","published_at":"2025-10-01T21:22:38.000Z","date":"2025-09-29","kind":"sale","planned":false,"acquired":false,"shares":3390943,"price":7.58,"value":25703347.94,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents the weighted average sale price of Class A Ordinary Shares (\"Shares\") sold in a series of open market transactions on the transaction date at prices ranging from $7.30 to $8.18 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares sold at each price. All of these Shares were sold by the Master Fund, Fund II, Fund III, Fund IV, and the Account."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund II, LP (\"Fund II\"), Cormorant Private Healthcare Fund III, LP (\"Fund III\"), Cormorant Private Healthcare Fund IV, LP (\"Fund IV\") and a managed account (the \"Account\" and together with the Master Fund, Fund II, Fund III and Fund IV, the \"Funds\")). Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP II, LLC (\"GP II\"), Cormorant Private Healthcare GP III, LLC (\"GP III\") and Cormorant Private Healthcare GP IV, LLC (\"GP IV\") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Represents (i) 1,532,978 Shares beneficially owned by the Master Fund, (ii) 1,018,717 Shares beneficially owned by Fund II, (iii) 1,386,674 Shares beneficially owned by Fund III, (iv) 847,642 Shares beneficially owned by Fund IV, and (v) 13,989 shares beneficially owned by the Account."}],"balance_after":4800000,"source":{"system":"sec-edgar","filing":"0000929638-25-003712","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963825003712/form4.xml","form_type":"4"}},{"id":1029421,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":2,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":74740,"kind":"organization","name":"Cormorant Private Healthcare Fund II, LP","position":4,"cik":"0001747677","reported_name":"Cormorant Private Healthcare Fund II, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":5,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":74741,"kind":"organization","name":"Cormorant Private Healthcare Fund IV LP","position":6,"cik":"0001871297","reported_name":"Cormorant Private Healthcare Fund IV LP","relationship":{"other":true,"other_text":"Former 10% Owner"}}],"security":"Class A Ordinary Shares","published_at":"2025-10-01T21:22:38.000Z","date":"2025-09-29","kind":"sale","planned":false,"acquired":false,"shares":232460,"price":8.4,"value":1952664.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price of Class A Ordinary Shares (\"Shares\") sold in a series of open market transactions on the transaction date at prices ranging from $8.20 to $9.02 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares sold at each price. All of these Shares were sold by the Master Fund, Fund II, Fund III, Fund IV, and the Account."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund II, LP (\"Fund II\"), Cormorant Private Healthcare Fund III, LP (\"Fund III\"), Cormorant Private Healthcare Fund IV, LP (\"Fund IV\") and a managed account (the \"Account\" and together with the Master Fund, Fund II, Fund III and Fund IV, the \"Funds\")). Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP II, LLC (\"GP II\"), Cormorant Private Healthcare GP III, LLC (\"GP III\") and Cormorant Private Healthcare GP IV, LLC (\"GP IV\") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Represents (i) 2,615,943 Shares beneficially owned by the Master Fund, (ii) 1,738,386 Shares beneficially owned by Fund II, (iii) 2,366,285 Shares beneficially owned by Fund III, (iv) 1,446,456 Shares beneficially owned by Fund IV, and (v) 23,873 shares beneficially owned by the Account."}],"balance_after":8190943,"source":{"system":"sec-edgar","filing":"0000929638-25-003712","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963825003712/form4.xml","form_type":"4"}},{"id":1029420,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":2,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":74740,"kind":"organization","name":"Cormorant Private Healthcare Fund II, LP","position":4,"cik":"0001747677","reported_name":"Cormorant Private Healthcare Fund II, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":5,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":74741,"kind":"organization","name":"Cormorant Private Healthcare Fund IV LP","position":6,"cik":"0001871297","reported_name":"Cormorant Private Healthcare Fund IV LP","relationship":{"other":true,"other_text":"Former 10% Owner"}}],"security":"Class A Ordinary Shares","published_at":"2025-10-01T21:22:38.000Z","date":"2025-09-29","kind":"sale","planned":false,"acquired":false,"shares":70748,"price":9.38,"value":663616.24,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of Class A Ordinary Shares (\"Shares\") sold in a series of open market transactions on the transaction date at prices ranging from $9.25 to $9.43 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares sold at each price. All of these Shares were sold by the Master Fund (as defined below) , Fund II (as defined below), Fund III (as defined below), Fund IV (as defined below), and the Account (as defined below)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund II, LP (\"Fund II\"), Cormorant Private Healthcare Fund III, LP (\"Fund III\"), Cormorant Private Healthcare Fund IV, LP (\"Fund IV\") and a managed account (the \"Account\" and together with the Master Fund, Fund II, Fund III and Fund IV, the \"Funds\")). Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP II, LLC (\"GP II\"), Cormorant Private Healthcare GP III, LLC (\"GP III\") and Cormorant Private Healthcare GP IV, LLC (\"GP IV\") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents (i) 2,690,183 Shares beneficially owned by the Master Fund, (ii) 1,787,722 Shares beneficially owned by Fund II, (iii) 2,433,441 Shares beneficially owned by Fund III, (iv) 1,487,507 Shares beneficially owned by Fund IV, and (v) 24,550 shares beneficially owned by the Account."}],"balance_after":8423403,"source":{"system":"sec-edgar","filing":"0000929638-25-003712","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963825003712/form4.xml","form_type":"4"}},{"id":1142937,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":2,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":3,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":74741,"kind":"organization","name":"Cormorant Private Healthcare Fund IV LP","position":4,"cik":"0001871297","reported_name":"Cormorant Private Healthcare Fund IV LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25048,"kind":"organization","name":"Cormorant Private Healthcare Fund V LP","position":5,"cik":"0001969296","reported_name":"Cormorant Private Healthcare Fund V LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25044,"kind":"person","name":"Chen Bihua","position":6,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"other":true,"other_text":"Former 10% Owner"}}],"security":"Class A Common Stock","published_at":"2025-05-19T21:33:06.000Z","date":"2025-05-15","kind":"sale","planned":false,"acquired":false,"shares":1813439,"price":1.8545,"value":3363022.6255,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of Class A Common Stock (the \"shares\") sold in a series of open market transactions on the transaction date ranging from $1.85 to $2.03 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Cormorant Asset Management, LP serves as the investment manager to Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund III, LP (\"Fund III\"), Cormorant Private Healthcare Fund IV, LP (\"Fund IV\") and Cormorant Private Healthcare Fund V, LP (\"Fund V\"). Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare GP IV, LLC and Cormorant Private Healthcare GP V, LLC serve as the general partners of the Master Fund, Fund III, Fund IV and Fund V, respectively. Bihua Chen serves as the managing member of Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare GP IV, LLC and Cormorant Private Healthcare GP V, LLC, and the general partner of Cormorant Asset Management, LP."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000929638-25-001950","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963825001950/form4.xml","form_type":"4"}},{"id":1149321,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":2,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":3,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"ten_percent_owner":true}},{"id":74741,"kind":"organization","name":"Cormorant Private Healthcare Fund IV LP","position":4,"cik":"0001871297","reported_name":"Cormorant Private Healthcare Fund IV LP","relationship":{"ten_percent_owner":true}},{"id":25048,"kind":"organization","name":"Cormorant Private Healthcare Fund V LP","position":5,"cik":"0001969296","reported_name":"Cormorant Private Healthcare Fund V LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":6,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}}],"security":"Class A Common Stock","published_at":"2025-05-14T20:36:04.000Z","date":"2025-05-12","kind":"sale","planned":false,"acquired":false,"shares":24300,"price":1.985,"value":48235.5,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Cormorant Asset Management, LP serves as the investment manager to Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund III, LP (\"Fund III\"), Cormorant Private Healthcare Fund IV, LP (\"Fund IV\") and Cormorant Private Healthcare Fund V, LP (\"Fund V\"). Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare GP IV, LLC and Cormorant Private Healthcare GP V, LLC serve as the general partners of the Master Fund, Fund III, Fund IV and Fund V, respectively. Bihua Chen serves as the managing member of Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare GP IV, LLC and Cormorant Private Healthcare GP V, LLC, and the general partner of Cormorant Asset Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents (i) 429,934 shares of Class A Common Stock beneficially owned by the Master Fund, (ii) 1,099,451 shares of Class A Common Stock beneficially owned by Fund III, (iii) 234,125 shares of Class A Common Stock beneficially owned by Fund IV, and (iv) 49,929 shares of Class A Common Stock beneficially owned by Fund V."}],"balance_after":1813439,"source":{"system":"sec-edgar","filing":"0000929638-25-001870","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963825001870/form4.xml","form_type":"4"}},{"id":1396780,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25048,"kind":"organization","name":"Cormorant Private Healthcare Fund V LP","position":2,"cik":"0001969296","reported_name":"Cormorant Private Healthcare Fund V LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25044,"kind":"person","name":"Chen Bihua","position":3,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":74741,"kind":"organization","name":"Cormorant Private Healthcare Fund IV LP","position":4,"cik":"0001871297","reported_name":"Cormorant Private Healthcare Fund IV LP","relationship":{"other":true,"other_text":"Former 10% Owner"}}],"security":"Series D Redeemable Convertible Preferred Stock","published_at":"2024-10-01T20:01:04.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":false,"shares":5263772,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Series D Redeemable Convertible Preferred Stock (\"Series D Preferred Stock\") automatically converted into 0.224084614 shares of Common Stock of the Issuer (\"Common Stock\") upon the closing of the Issuer's initial public offering of Common Stock.  The Series D Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series D Redeemable Convertible Preferred Stock (\"Series D Preferred Stock\") automatically converted into 0.224084614 shares of Common Stock of the Issuer (\"Common Stock\") upon the closing of the Issuer's initial public offering of Common Stock.  The Series D Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Series D Redeemable Convertible Preferred Stock (\"Series D Preferred Stock\") automatically converted into 0.224084614 shares of Common Stock of the Issuer (\"Common Stock\") upon the closing of the Issuer's initial public offering of Common Stock.  The Series D Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Series D Redeemable Convertible Preferred Stock (\"Series D Preferred Stock\") automatically converted into 0.224084614 shares of Common Stock of the Issuer (\"Common Stock\") upon the closing of the Issuer's initial public offering of Common Stock.  The Series D Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Each share of the Series D Redeemable Convertible Preferred Stock (\"Series D Preferred Stock\") automatically converted into 0.224084614 shares of Common Stock of the Issuer (\"Common Stock\") upon the closing of the Issuer's initial public offering of Common Stock.  The Series D Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents (i) 173,704 shares of Series D Preferred Stock beneficially owned by the Master Fund (defined below), which converted into 38,924 shares of Common Stock, (ii) 2,769,271 shares of Series D Preferred Stock beneficially owned by Fund IV (defined below), which converted into 620,551 shares of Common Stock, and (iii) 2,320,797 shares of Series D Preferred Stock beneficially owned by Fund V (defined below), which converted into 520,054 shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund IV, LP (\"Fund IV\") and Cormorant Private Healthcare Fund V, LP (\"Fund V\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP IV, LLC (\"GP IV\") and Cormorant Private Healthcare GP V, LLC (\"GP V\") serve as General Partner of the Master Fund, Fund IV and Fund V, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP IV  and GP V. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1179529},"source":{"system":"sec-edgar","filing":"0000929638-24-003363","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000092963824003363/form4.xml","form_type":"4"}},{"id":1396779,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25048,"kind":"organization","name":"Cormorant Private Healthcare Fund V LP","position":2,"cik":"0001969296","reported_name":"Cormorant Private Healthcare Fund V LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25044,"kind":"person","name":"Chen Bihua","position":3,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":74741,"kind":"organization","name":"Cormorant Private Healthcare Fund IV LP","position":4,"cik":"0001871297","reported_name":"Cormorant Private Healthcare Fund IV LP","relationship":{"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2024-10-01T20:01:04.000Z","date":"2024-09-27","kind":"purchase","planned":false,"acquired":true,"shares":450000,"price":18,"value":8100000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund IV, LP (\"Fund IV\") and Cormorant Private Healthcare Fund V, LP (\"Fund V\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP IV, LLC (\"GP IV\") and Cormorant Private Healthcare GP V, LLC (\"GP V\") serve as General Partner of the Master Fund, Fund IV and Fund V, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP IV  and GP V. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares of Common Stock purchased for the account of the Master Fund."}],"balance_after":1629529,"source":{"system":"sec-edgar","filing":"0000929638-24-003363","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000092963824003363/form4.xml","form_type":"4"}},{"id":1396778,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25048,"kind":"organization","name":"Cormorant Private Healthcare Fund V LP","position":2,"cik":"0001969296","reported_name":"Cormorant Private Healthcare Fund V LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25044,"kind":"person","name":"Chen Bihua","position":3,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":74741,"kind":"organization","name":"Cormorant Private Healthcare Fund IV LP","position":4,"cik":"0001871297","reported_name":"Cormorant Private Healthcare Fund IV LP","relationship":{"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2024-10-01T20:01:04.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":true,"shares":1179529,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series D Redeemable Convertible Preferred Stock (\"Series D Preferred Stock\") automatically converted into 0.224084614 shares of Common Stock of the Issuer (\"Common Stock\") upon the closing of the Issuer's initial public offering of Common Stock.  The Series D Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Each share of the Series D Redeemable Convertible Preferred Stock (\"Series D Preferred Stock\") automatically converted into 0.224084614 shares of Common Stock of the Issuer (\"Common Stock\") upon the closing of the Issuer's initial public offering of Common Stock.  The Series D Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents (i) 173,704 shares of Series D Preferred Stock beneficially owned by the Master Fund (defined below), which converted into 38,924 shares of Common Stock, (ii) 2,769,271 shares of Series D Preferred Stock beneficially owned by Fund IV (defined below), which converted into 620,551 shares of Common Stock, and (iii) 2,320,797 shares of Series D Preferred Stock beneficially owned by Fund V (defined below), which converted into 520,054 shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund IV, LP (\"Fund IV\") and Cormorant Private Healthcare Fund V, LP (\"Fund V\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP IV, LLC (\"GP IV\") and Cormorant Private Healthcare GP V, LLC (\"GP V\") serve as General Partner of the Master Fund, Fund IV and Fund V, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP IV  and GP V. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":1179529,"source":{"system":"sec-edgar","filing":"0000929638-24-003363","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000092963824003363/form4.xml","form_type":"4"}},{"id":1762673,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":2,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":74740,"kind":"organization","name":"Cormorant Private Healthcare Fund II, LP","position":4,"cik":"0001747677","reported_name":"Cormorant Private Healthcare Fund II, LP","relationship":{"ten_percent_owner":true}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":5,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"ten_percent_owner":true}},{"id":74741,"kind":"organization","name":"Cormorant Private Healthcare Fund IV LP","position":6,"cik":"0001871297","reported_name":"Cormorant Private Healthcare Fund IV LP","relationship":{"ten_percent_owner":true}}],"security":"Class A Ordinary Shares","published_at":"2023-10-10T20:00:43.000Z","date":"2023-10-05","kind":"purchase","planned":false,"acquired":true,"shares":58839,"price":59.8973,"value":3524297.2347,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of Class A Ordinary Shares (\"Shares\") purchased in a series of open market transactions on the transaction date at prices ranging from $59.78 to $59.90 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares purchased at each price. All of these Shares were purchased by the Master Fund (as defined below)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund II, LP (\"Fund II\"), Cormorant Private Healthcare Fund III, LP (\"Fund III\"), Cormorant Private Healthcare Fund IV, LP (\"Fund IV\") and a managed account (the \"Account\" and together with the Master Fund, Fund II, Fund III and Fund IV, the \"Funds\")). Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP II, LLC (\"GP II\"), Cormorant Private Healthcare GP III, LLC (\"GP III\") and Cormorant Private Healthcare GP IV, LLC (\"GP IV\") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents (i) 2,712,779 Shares beneficially owned by the Master Fund, (ii) 1,802,737 Shares beneficially owned by Fund II, (iii) 2,453,879 Shares beneficially owned by Fund III, (iv) 1,500,000 Shares beneficially owned by Fund IV, and (v) 24,756 shares beneficially owned by the Account."}],"balance_after":8494151,"source":{"system":"sec-edgar","filing":"0000929638-23-002739","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963823002739/form4.xml","form_type":"4"}},{"id":1765455,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":2,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":74740,"kind":"organization","name":"Cormorant Private Healthcare Fund II, LP","position":4,"cik":"0001747677","reported_name":"Cormorant Private Healthcare Fund II, LP","relationship":{"ten_percent_owner":true}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":5,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"ten_percent_owner":true}},{"id":74741,"kind":"organization","name":"Cormorant Private Healthcare Fund IV LP","position":6,"cik":"0001871297","reported_name":"Cormorant Private Healthcare Fund IV LP","relationship":{"ten_percent_owner":true}}],"security":"Class A Ordinary Shares","published_at":"2023-10-04T21:52:22.000Z","date":"2023-10-04","kind":"purchase","planned":false,"acquired":true,"shares":67814,"price":57.3188,"value":3887017.1032,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents the weighted average sale price of Class A Ordinary Shares (\"Shares\") purchased in a series of open market transactions on the transaction date at prices ranging from $56.88 to $57.60 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares purchased at each price. All of these Shares were purchased by the Master Fund (as defined below)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund II, LP (\"Fund II\"), Cormorant Private Healthcare Fund III, LP (\"Fund III\"), Cormorant Private Healthcare Fund IV, LP (\"Fund IV\") and a managed account (the \"Account\" and together with the Master Fund, Fund II, Fund III and Fund IV, the \"Funds\")). Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP II, LLC (\"GP II\"), Cormorant Private Healthcare GP III, LLC (\"GP III\") and Cormorant Private Healthcare GP IV, LLC (\"GP IV\") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Persons disclaims beneficial ownership of the ordinary shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares reported herein reflect a distribution of Shares previously owned by Helix Holdings LLC (\"Helix\") to the Funds on a pro rata basis in accordance with their interests in Helix."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Prior to the purchases of Shares reported herein, (i) the Master Fund beneficially owned 2,360,728 Shares, (ii) Fund II beneficially owned 1,802,737 Shares, (iii) Fund III beneficially owned 2,453,879 Shares, (iv) Fund IV beneficially owned 1,500,000 Shares, and (v) the Account beneficially owned 24,756 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Represents (i) 2,653,940 Shares beneficially owned by the Master Fund, (ii) 1,802,737 Shares beneficially owned by Fund II, (iii) 2,453,879 Shares beneficially owned by Fund III, (iv) 1,500,000 Shares beneficially owned by Fund IV, and (v) 24,756 shares beneficially owned by the Account."}],"balance_after":8435312,"source":{"system":"sec-edgar","filing":"0000929638-23-002692","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963823002692/form4.xml","form_type":"4"}},{"id":1765454,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":2,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":74740,"kind":"organization","name":"Cormorant Private Healthcare Fund II, LP","position":4,"cik":"0001747677","reported_name":"Cormorant Private Healthcare Fund II, LP","relationship":{"ten_percent_owner":true}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":5,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"ten_percent_owner":true}},{"id":74741,"kind":"organization","name":"Cormorant Private Healthcare Fund IV LP","position":6,"cik":"0001871297","reported_name":"Cormorant Private Healthcare Fund IV LP","relationship":{"ten_percent_owner":true}}],"security":"Class A Ordinary Shares","published_at":"2023-10-04T21:52:22.000Z","date":"2023-10-03","kind":"purchase","planned":false,"acquired":true,"shares":150487,"price":57.252,"value":8615681.724,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents the weighted average sale price of Class A Ordinary Shares (\"Shares\") purchased in a series of open market transactions on the transaction date at prices ranging from $56.87 to $57.50 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares purchased at each price. All of these Shares were purchased by the Master Fund (as defined below)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund II, LP (\"Fund II\"), Cormorant Private Healthcare Fund III, LP (\"Fund III\"), Cormorant Private Healthcare Fund IV, LP (\"Fund IV\") and a managed account (the \"Account\" and together with the Master Fund, Fund II, Fund III and Fund IV, the \"Funds\")). Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP II, LLC (\"GP II\"), Cormorant Private Healthcare GP III, LLC (\"GP III\") and Cormorant Private Healthcare GP IV, LLC (\"GP IV\") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Persons disclaims beneficial ownership of the ordinary shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares reported herein reflect a distribution of Shares previously owned by Helix Holdings LLC (\"Helix\") to the Funds on a pro rata basis in accordance with their interests in Helix."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Prior to the purchases of Shares reported herein, (i) the Master Fund beneficially owned 2,360,728 Shares, (ii) Fund II beneficially owned 1,802,737 Shares, (iii) Fund III beneficially owned 2,453,879 Shares, (iv) Fund IV beneficially owned 1,500,000 Shares, and (v) the Account beneficially owned 24,756 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Represents (i) 2,586,126 Shares beneficially owned by the Master Fund, (ii) 1,802,737 Shares beneficially owned by Fund II, (iii) 2,453,879 Shares beneficially owned by Fund III, (iv) 1,500,000 Shares beneficially owned by Fund IV, and (v) 24,756 shares beneficially owned by the Account."}],"balance_after":8367498,"source":{"system":"sec-edgar","filing":"0000929638-23-002692","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963823002692/form4.xml","form_type":"4"}},{"id":1765453,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":2,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":74740,"kind":"organization","name":"Cormorant Private Healthcare Fund II, LP","position":4,"cik":"0001747677","reported_name":"Cormorant Private Healthcare Fund II, LP","relationship":{"ten_percent_owner":true}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":5,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"ten_percent_owner":true}},{"id":74741,"kind":"organization","name":"Cormorant Private Healthcare Fund IV LP","position":6,"cik":"0001871297","reported_name":"Cormorant Private Healthcare Fund IV LP","relationship":{"ten_percent_owner":true}}],"security":"Class A Ordinary Shares","published_at":"2023-10-04T21:52:22.000Z","date":"2023-10-02","kind":"purchase","planned":false,"acquired":true,"shares":74911,"price":57.37,"value":4297644.07,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of Class A Ordinary Shares (\"Shares\") purchased in a series of open market transactions on the transaction date at prices ranging from $56.75 to $57.62 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares purchased at each price. All of these Shares were purchased by the Master Fund (as defined below)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund II, LP (\"Fund II\"), Cormorant Private Healthcare Fund III, LP (\"Fund III\"), Cormorant Private Healthcare Fund IV, LP (\"Fund IV\") and a managed account (the \"Account\" and together with the Master Fund, Fund II, Fund III and Fund IV, the \"Funds\")). Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP II, LLC (\"GP II\"), Cormorant Private Healthcare GP III, LLC (\"GP III\") and Cormorant Private Healthcare GP IV, LLC (\"GP IV\") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Persons disclaims beneficial ownership of the ordinary shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares reported herein reflect a distribution of Shares previously owned by Helix Holdings LLC (\"Helix\") to the Funds on a pro rata basis in accordance with their interests in Helix."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Prior to the purchases of Shares reported herein, (i) the Master Fund beneficially owned 2,360,728 Shares, (ii) Fund II beneficially owned 1,802,737 Shares, (iii) Fund III beneficially owned 2,453,879 Shares, (iv) Fund IV beneficially owned 1,500,000 Shares, and (v) the Account beneficially owned 24,756 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Represents (i) 2,435,639 Shares beneficially owned by the Master Fund, (ii) 1,802,737 Shares beneficially owned by Fund II, (iii) 2,453,879 Shares beneficially owned by Fund III, (iv) 1,500,000 Shares beneficially owned by Fund IV, and (v) 24,756 shares beneficially owned by the Account."}],"balance_after":8217011,"source":{"system":"sec-edgar","filing":"0000929638-23-002692","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963823002692/form4.xml","form_type":"4"}},{"id":2435676,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":74741,"kind":"organization","name":"Cormorant Private Healthcare Fund IV LP","position":4,"cik":"0001871297","reported_name":"Cormorant Private Healthcare Fund IV LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Series B Convertible Preferred Stock","published_at":"2022-01-13T21:06:53.000Z","date":"2022-01-11","kind":"exercise","acquired":false,"shares":616786,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Shares of Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares of Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares of Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Shares of Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\") and Cormorant Private Healthcare Fund IV, LP (\"Fund IV\"). Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of the Master Fund and Fund IV. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Series B Convertible Preferred Stock represented, on an as-converted basis, (i) 11,163 shares held by the Master Fund and (ii) 605,623 shares held by Fund IV."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":616786},"source":{"system":"sec-edgar","filing":"0001567619-22-001163","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583977/000156761922001163/doc1.xml","form_type":"4"}},{"id":2435675,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":74741,"kind":"organization","name":"Cormorant Private Healthcare Fund IV LP","position":4,"cik":"0001871297","reported_name":"Cormorant Private Healthcare Fund IV LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2022-01-13T21:06:53.000Z","date":"2022-01-11","kind":"exercise","acquired":true,"shares":616786,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares of Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\") and Cormorant Private Healthcare Fund IV, LP (\"Fund IV\"). Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of the Master Fund and Fund IV. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents (i) 11,163 shares held by the Master Fund and (ii) 605,623 shares held by Fund IV."}],"balance_after":616786,"source":{"system":"sec-edgar","filing":"0001567619-22-001163","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583977/000156761922001163/doc1.xml","form_type":"4"}}]}